click below
click below
Normal Size Small Size show me how
MDA Blankenship
MDA-Midterm
| DRUG | MDA | Indication |
|---|---|---|
| Physostigmine | Reversible cholinesterase Inhibitor | Glaucoma (tertiary amine) |
| Neostigmine | Reversible cholinesterase Inhibitor | postoperative/post partum atony of GI tract or urinary bladder, Myasthenia gravis |
| Diisopropylfluorophosphate (DFP) | Irreversible cholinesterase Inhibitor (binds to OH is esteric site) | pesticide/nerve gas (organophosphate) |
| Echothiophate | Irreversible cholinesterase Inhibitor (binds to OH is esteric site) | Glaucoma (organophosphate) |
| Pralidoxine (2PAM) | Cholesterase reactivator | binds to anionic site on cholinesterase to remove organophosphate |
| Atropine | competitive, muscarinic antagonist | control GI sensitivity; decrease respitory secretion; increase HR (CNS excitation) |
| Scopolamine | muscarinic antagonist | insomnia; preansthetic agent; motion sickness (CNS depressant) |
| Quaternary amines: Propantheline, Clidinium | muscarinic antagonist | Periphery effects, decrease GI motility; antispasmotic No CNS side effects |
| Homotropine, Tropicamide | muscarinic antagonist | dilation of the eye (Mydriatic Agents) |
| Ipratropium Bromide | muscarinic antagonist | COPD (blocks bronchoconstriction) |
| Mecamylamine | nicotinic antagonist (Ganglionic blocker) | severe hypertension |
| Pancuronium Bromide, Atracurium, Mivacurium | Competative neuromuscular Junction blocker | general ansthetics; severe convulsions |
| Succinylcholine | Non-Competative neuromuscular Junction blocker | general ansthetics; severe convulsions |
| Norepinephrine (Levarterenol) | α1, α2, β1 agonist | primary cardiovascular effects |
| Epinephrine | α1, α2, β1, β2 agonist | Cardiac stimulation, anaphylaxis, asthma |
| Isoproterenol | β1, β2 agonist | Bronchodilator (reflex tachycardia) |
| Dobutamine | Selective β1 agonist | Cardiac stimulant |
| Dopamine (DA) | D1 agonist | |
| Tyramine (also from aged food) | Indirect - replaces NE in the vesicle causing its release and response | NE effectsα1 vasoconstriction; β1 cardio stimulant (Amphetamine - crosses BBB) Tolerance due to lack of NE left |
| Ephedrine | Indirect - Replaces NE and has direct β2 agonist properties | bronchodilator(crosses BBB) |
| Pseudoephedrine | Indirect - optical isomer of Ephedrine - indirect releaser of NE | nasal decongestant (vasoconstriciton) |
| Phenylpropanolamine | Indirect - looks allot line NE and EPI - indirect releaser | |
| Methylphenidate | indirect releaser | ADHD; appetite suppression |
| Cocaine | Indirect - NE and Epi reuptake blocker | |
| Phenylaphrine | direct - selective α1 agonist | nasal decongestant spray (vasoconstriciton), induce mydriasis |
| Clonidine | direct - selective α2 agonist | antihypertensive |
| Metaproterenol, Terbutaline, Albuterol, Salmeterol | β2 agonist | bronchodilator; prevention of premature delivery, |
| Prazosin | competitive reversible α1 antagonist | antihypertensive |
| Phenoxybenzamine | Non-competitive irreversible α1, α2 antagonist | control BP during surgery; Reynaud's syndrome |
| Propranolol | competitive β1, β2 antagonist | anti-hypertensive; anti-angina; anti-arrhythmic; thyrotoxicosis; Anti-anxiety |
| Metoprolol | β1 antagonist | antihypertensive, can be used in asthma |
| Labetulol, Carvedilol | α1, β1, β2 antagonist | antihypertensive |
| Bethanechol | Muscarinic Agonist | postoperative/post partum atony of GI tract or urinary bladder |